Tweetovi
- Tweetovi, trenutna stranica.
- Tweetovi i odgovori
- Medijski sadržaj
Blokirali ste korisnika/cu @COGorg
Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @COGorg
-
Prikvačeni tweet
Vincristine Shortage – A Letter to the Childhood Cancer Community from Dr. Peter Adamson, Chair of the Children's Oncology Grouppic.twitter.com/vrBUbZGvNS
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Mixed‐phenotype acute leukemia: A cohort and consensus research strategy from the Children’s Oncology Group Acute Leukemia of Ambiguous Lineage Task Forcehttps://acsjournals.onlinelibrary.wiley.com/doi/full/10.1002/cncr.32552#.XjJC6k_G9ns.twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children’s Oncology Group proslijedio/la je Tweet
Newly Activated
#NCTN#Braincancer Trial: (ACNS1833) A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma, led by@COGorg. Learn more: https://buff.ly/2FrkJry pic.twitter.com/HomKRszs3p
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children’s Oncology Group ARAR0331 Studyhttps://ascopubs.org/doi/abs/10.1200/JCO.19.01276?af=R#.XgqKX6MjF84.twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Inotuzumab Ozogamicin Shows Clinical Efficacy in Relapsed Pediatric B-ALLhttps://www.cancertherapyadvisor.com/home/news/conference-coverage/american-society-of-hematology-ash/ash-2019/bcell-acute-leukemia-inotuzumab-ozagomicin-shows-clinical-efficacy/ …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Those treated with blinatumomab had longer survival, experienced fewer severe side effects, had a higher rate of undetectable residual disease, and were more likely to proceed to a stem cell transplant.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
New findings from a clinical trial show that treatment with the immunotherapy drug blinatumomab is superior to standard chemotherapy for children and young adults with high- or intermediate-risk B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed.
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Blinatumomab improves outcomes in relapsed pediatric leukemia https://www.cancer.gov/news-events/press-releases/2019/blinatumomab-relapsed-all?cid=eb_govdel …pic.twitter.com/8T39OyAv8F
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Survival by Race and Ethnicity in Pediatric and Adolescent Patients With Hodgkin Lymphoma: A Children’s Oncology Group Studyhttps://ascopubs.org/doi/abs/10.1200/JCO.19.00812#.XgpztvrBA7c.twitter …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Results of Children’s Oncology Group Trial AALL0331 suggest intensified postinduction therapy does not significantly improve outcomes over standard consolidation for patients with standard-risk ALLhttps://www.clinicaloncology.com/Hematologic-Malignancies/Article/12-19/Report-from-ASH-2019-Large-Benefit-With-Blinatumomab-in-Trial-of-Younger-B-ALL-Patients/56897 …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Outcome in Children With Standard-Risk B-Cell Acute Lymphoblastic Leukemia: Results of Children’s Oncology Group Trial AALL0331https://ascopubs.org/doi/abs/10.1200/JCO.19.01086?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&journalCode=jco#.XgpxUXISl48.twitter …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children’s Oncology Group proslijedio/la je Tweet
NCI Press Release:
#NCTN@COGorg trial AALL1331 found that after completion of reinduction therapy, blinatumomab is superior to standard chemotherapy for certain children and young adults with relapsed B-cell acute lymphoblastic leukemia. Learn more: https://buff.ly/2Rz1T9o pic.twitter.com/9ZR7e1iJTq
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children’s Oncology Group proslijedio/la je Tweet
'Tis the season! The MLS WORKS
#KickChildhoodCancer Holiday Auction is now open! Bid on match-used & autographed jerseys & match balls with net proceed benefitting@COGorg.
: http://soc.cr/B75V50xks14 pic.twitter.com/MKIYn2PSKc
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children’s Oncology Group proslijedio/la je Tweet
Want to improve care and outcomes for
#AYA cancer patients? Join the@TheCTSU webinar on dec 3rd to learn how to increase#AYA enrollment onto clinical trials. Need AYAs on trials to determine optimal treatment approaches.@theNCI@COGorg@SWOG@eaonc@NRGonc#ayacsmhttps://twitter.com/NCICTEP_ClinRes/status/1194268866047811587 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children’s Oncology Group proslijedio/la je Tweet
ALL-directed chemo w/o hematopoietic stem cell transplantation may be sufficient therapy for most children with WHO2016-defined MPAL. The proposed prospective trial will investigate this approach and explore MPAL genomics and correlative biology. http://ow.ly/Rgxo30pNUYP
@COGorgpic.twitter.com/qbkCH1DDDK
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
If you missed the Vincristine drug shortage update webinar, it was recorded and available to watch via this link https://youtu.be/egfudrUGfYE https://twitter.com/COGorg/status/1187034273380880384 …
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
You are invited to an informational webinar presented by Dr. Peter Adamson, Chair of the Children’s Oncology Group. Dr. Adamson will share information and a perspective on childhood cancer drug shortages, including the current situation with vincristine. http://bit.ly/31AHKRJ pic.twitter.com/fUbyztoKJf
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Children’s Oncology Group proslijedio/la je Tweet
You are invited to an informational webinar presented by Dr. Peter Adamson, Chair of the Children’s Oncology Group. Dr. Adamson will share information and a perspective on childhood cancer drug shortages, including the current situation with vincristine. http://bit.ly/31AHKRJ pic.twitter.com/m3H73NzggP
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Peter Adamson, Chair of the Children’s Oncology Group, was interviewed by
@nbcnews about the#vincristine shortage. . Shortage of critical children’s cancer drug causes concerns nationwidehttps://www.nbcnews.com/nightly-news/video/shortage-of-critical-children-s-cancer-drug-causes-concerns-nationwide-71636037609 …Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
....children’s cancer, acute lymphoblastic leukemia, then less often as a maintenance therapy for two to three years. Children newly diagnosed with the leukemia are given the highest priority if vincristine is scarce."https://www.inquirer.com/health/vincristine-shortage-childhood-cancer-drug-fda-pfizer-20191017.html …
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi -
Dr. Peter Adamson quoted in the
@PhillyInquirer article, regarding vincristine shortage, "Vincristine is used to treat 80% of the 19,000 children and adolescents diagnosed with cancer each year. It is given once a week for four weeks to induce remission in the most common...Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.